Product Images Lurasidone Hydrochloride

This text provides information about a medication called Lurasidone Hydrochloride Tablet. It includes details on dosage and administration, as well as instructions for pharmacists on dispensing the medication to each patient separately. Additionally, it references a guide available at avefpharma.com for further information. The NDC (National Drug Code) for the medication is 23155-891-03, and it comes in a package of 30 tablets.*

This is a description of Lurasidone Hydrochloride Tablets, 120 mg with a total quantity of 10 Kg. The batch number is listed as LLLLLLL, and there are approximately 20,000 tablets per batch. The manufacturing date and the package before date are required in YYYY/MM format. The NDC Number is 23155-891-18. The storage instructions advise preserving in tight containers at 20° to 26°C (68° to 77°F), with excursions allowed between 15° to 30°C (59° to 86°F) as per USP Controlled Room Temperature guidelines. The caution mentions the product is for manufacturing, processing, or repacking. The manufacturer is Avet Pharmaceuticals Labs Inc. based in East Brunswick, NJ 08816.*

This is a description of Lurasidone Hydrochloride Tablets in 20 mg strength. The batch quantity is 10 kg with a manufacturing date and an approximate count of 121,000 tablets. The tablets come with a Package Before Date, NDC Number, and storage instructions. They should be stored in tight containers at a temperature range of 20°C to 25°C with excursions permitted between 15°C to 30°C. The manufacturer is Avet Pharmaceuticals Labs Inc. from East Brunswick, NJ 08816.*

This information pertains to Lurasidone Hydrochloride Tablets 40 mg. It includes details such as batch number, quantity, manufacturing date, expiry date, prescription information, NDC number, storage instructions, and caution for use. The tablets are manufactured by Avet Pharmaceuticals Labs Inc. in East Brunswick, NJ 08816.*

This appears to be a description of a medication product labeled as "Lurasidone Hydrochloride Tablet" from a company called Avet Pharma. The product comes with a guide available at their website www.avetpharma.com. The package contains 90 tablets and has a unique code NDC 23155-889-09. Additionally, the pharmacists are advised to dispense the medication separately to each patient.*

This information contains details about Lurasidone Hydrochloride Tablets 60 mg, including the batch number, quantity, manufacturing date, and storage instructions. It specifies that there are approximately 40,000 tablets in the batch. The tablets are prescription-only with an NDC number provided. The storage temperature is advised to be between 20°C to 26°C, with permissible excursions between 15°C to 30°C. The manufacturer is Avet Pharmaceuticals Labs Inc. from East Brunswick, NJ 08816.*

This text provides information about Lurasidone Hydrochloride Tablets 80 mg, including manufacturing date, package expiration date, NDC number, quantity, storage instructions, and caution for use. The tablets are manufactured by Avet Pharmaceuticals Labs Inc. in East Brunswick, NJ 08816. Storage instructions recommend keeping the tablets in tight containers at 20° to 25°C, with excursions permitted between 15° to 30°C.*

This text discusses the impact of different drugs on the pharmacokinetics of Lurasidone. It includes information on the fold change in pharmacokinetic parameters (Cmax and AUC) and 90% confidence intervals for various interacting drugs categorized as strong CYP3A4 inhibitor (Ketoconazole), moderate CYP3A4 inhibitor (Diltiazem), and strong CYP3A4 inducer (Rifampin). Additionally, it mentions the effects of Lithium on Cmax and AUC of Lurasidone. The data presented indicate changes relative to Lurasidone alone.*

This text provides a list of interacting drugs including P-gp Substrates like Digoxin and CYP3A4 Substrates like Midazolam. It also mentions an Oral Contraceptive, Lithium, and PK parameters such as Cmax, Auc, and Ctrough. The data includes Fold Change and 90% CI information related to drug interactions.*

This text appears to be a summary of data related to renal impairment, hepatic impairment, population description, gender comparison, pharmacokinetics, and fold change. It may be a part of a study or research project focusing on the effects of varying levels of renal and hepatic impairment on different populations and genders. The text seems to present comparisons and statistical analyses.*